|
|
|
|
Ian Somaiya
Managing Director
Biotechnology
+1 212.271.3761
isomaiya@tweisel.com
Ian Somaiya is a Managing Director at Thomas Weisel Partners LLC and covers Biotechnology. Ian has been recognized as the "Best on the Street" by the Wall Street Journal for his coverage on Biotechnology in 2006 and 2007. Formerly, Ian was a Senior Analyst at Morgan Stanley with responsibilities for small- and mid-capitalization biotechnology companies. He spent a year with The Carson Group in its Healthcare Consulting practice prior to making his transition to the sell side at Prudential Securities and later at Morgan Stanley. Ian also spent five years at the VA Hospital's Endocrinology Laboratory and at the Center for Neuroscience at New York University. Ian received a Bachelor of Arts degree in Biology/Neuroscience from New York University.
|
|
Coverage List
Ticker |
|
Company Name |
|
Rating |
|
Market Cap (mn) |
AFFY |
|
Affymax, Inc. |
|
Overweight |
|
$258 USD |
AMGN |
|
Amgen Inc. |
|
Overweight |
|
$67,407 USD |
AMLN |
|
Amylin Pharmaceuticals |
|
Market Weight |
|
$2,811 USD |
ARRY |
|
Array BioPharma Inc. |
|
Overweight |
|
$388 USD |
BIIB |
|
Biogen Idec Inc. |
|
Market Weight |
|
$14,829 USD |
CELG |
|
Celgene Corporation |
|
Overweight |
|
$32,229 USD |
DCGN |
|
deCODE genetics, Inc. |
|
Market Weight |
|
$71 USD |
DNA |
|
Genentech, Inc. |
|
Market Weight |
|
$103,348 USD |
GENZ |
|
Genzyme Corporation |
|
Overweight |
|
$21,046 USD |
GILD |
|
Gilead Sciences, Inc. |
|
Overweight |
|
$49,445 USD |
HGSI |
|
Human Genome Sciences, Inc. |
|
Overweight |
|
$957 USD |
MBRX |
|
Metabasis Therapeutics, Inc. |
|
Market Weight |
|
$55 USD |
NBIX |
|
Neurocrine Biosciences, Inc. |
|
Market Weight |
|
$204 USD |
RIGL |
|
Rigel Pharmaceuticals, Inc. |
|
Overweight |
|
$836 USD |
THRX |
|
Theravance, Inc. |
|
Overweight |
|
$714 USD |
VRTX |
|
Vertex Pharmaceuticals Inc. |
|
Overweight |
|
$3,826 USD |
|
|
